{"id":2576,"date":"2020-09-22T15:46:20","date_gmt":"2020-09-22T05:46:20","guid":{"rendered":"\/eu-uk\/?p=2576"},"modified":"2021-09-09T16:15:25","modified_gmt":"2021-09-09T06:15:25","slug":"video-proactive-investors-interview-september-2020","status":"publish","type":"post","link":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/","title":{"rendered":"Video | Proactive Investors Interview &#8211; September 2020"},"content":{"rendered":"<p>Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.<\/p>\n<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/8S17LgmnK40\" width=\"701\" height=\"394\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.<\/p>\n","protected":false},"author":2,"featured_media":2592,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[3,1],"tags":[],"class_list":["post-2576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-media","category-video"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.9 - aioseo.com -->\n\t<meta name=\"description\" content=\"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Orthocell\"\/>\n\t<link rel=\"canonical\" href=\"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.9\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_GB\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Orthocell EU\/UK -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Video | Proactive Investors Interview \u2013 September 2020 - Orthocell EU\/UK\" \/>\n\t\t<meta property=\"og:description\" content=\"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.\" \/>\n\t\t<meta property=\"og:url\" content=\"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-09-22T05:46:20+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2021-09-09T06:15:25+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Video | Proactive Investors Interview \u2013 September 2020 - Orthocell EU\/UK\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#blogposting\",\"name\":\"Video | Proactive Investors Interview \\u2013 September 2020 - Orthocell EU\\\/UK\",\"headline\":\"Video | Proactive Investors Interview &#8211; September 2020\",\"author\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2020\\\/09\\\/Proactive-Interview-Sept-2020.png\",\"width\":1052,\"height\":590},\"datePublished\":\"2020-09-22T15:46:20+10:00\",\"dateModified\":\"2021-09-09T16:15:25+10:00\",\"inLanguage\":\"en-GB\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#webpage\"},\"articleSection\":\"Media, Video\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/video\\\/#listItem\",\"name\":\"Video\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/video\\\/#listItem\",\"position\":2,\"name\":\"Video\",\"item\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/video\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#listItem\",\"name\":\"Video | Proactive Investors Interview &#8211; September 2020\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#listItem\",\"position\":3,\"name\":\"Video | Proactive Investors Interview &#8211; September 2020\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/video\\\/#listItem\",\"name\":\"Video\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#organization\",\"name\":\"Orthocell EU\\\/UK\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/\",\"name\":\"Orthocell\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0aab809366bb46167bf34d1c56223f53c568b96a5870f19d01139e3e4a20c2f1?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Orthocell\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#webpage\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/\",\"name\":\"Video | Proactive Investors Interview \\u2013 September 2020 - Orthocell EU\\\/UK\",\"description\":\"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.\",\"inLanguage\":\"en-GB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2020\\\/09\\\/Proactive-Interview-Sept-2020.png\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#mainImage\",\"width\":1052,\"height\":590},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2020\\\/09\\\/22\\\/video-proactive-investors-interview-september-2020\\\/#mainImage\"},\"datePublished\":\"2020-09-22T15:46:20+10:00\",\"dateModified\":\"2021-09-09T16:15:25+10:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#website\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/\",\"name\":\"Orthocell EU\\\/UK\",\"inLanguage\":\"en-GB\",\"publisher\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Video | Proactive Investors Interview \u2013 September 2020 - Orthocell EU\/UK","description":"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.","canonical_url":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#blogposting","name":"Video | Proactive Investors Interview \u2013 September 2020 - Orthocell EU\/UK","headline":"Video | Proactive Investors Interview &#8211; September 2020","author":{"@id":"\/eu-uk\/blog\/author\/hcartres\/#author"},"publisher":{"@id":"\/eu-uk\/#organization"},"image":{"@type":"ImageObject","url":"\/eu-uk\/wp-content\/uploads\/sites\/6\/2020\/09\/Proactive-Interview-Sept-2020.png","width":1052,"height":590},"datePublished":"2020-09-22T15:46:20+10:00","dateModified":"2021-09-09T16:15:25+10:00","inLanguage":"en-GB","mainEntityOfPage":{"@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#webpage"},"isPartOf":{"@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#webpage"},"articleSection":"Media, Video"},{"@type":"BreadcrumbList","@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/orthocell.com\/eu-uk#listItem","position":1,"name":"Home","item":"https:\/\/orthocell.com\/eu-uk","nextItem":{"@type":"ListItem","@id":"\/eu-uk\/blog\/category\/video\/#listItem","name":"Video"}},{"@type":"ListItem","@id":"\/eu-uk\/blog\/category\/video\/#listItem","position":2,"name":"Video","item":"\/eu-uk\/blog\/category\/video\/","nextItem":{"@type":"ListItem","@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#listItem","name":"Video | Proactive Investors Interview &#8211; September 2020"},"previousItem":{"@type":"ListItem","@id":"https:\/\/orthocell.com\/eu-uk#listItem","name":"Home"}},{"@type":"ListItem","@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#listItem","position":3,"name":"Video | Proactive Investors Interview &#8211; September 2020","previousItem":{"@type":"ListItem","@id":"\/eu-uk\/blog\/category\/video\/#listItem","name":"Video"}}]},{"@type":"Organization","@id":"\/eu-uk\/#organization","name":"Orthocell EU\/UK","url":"\/eu-uk\/"},{"@type":"Person","@id":"\/eu-uk\/blog\/author\/hcartres\/#author","url":"\/eu-uk\/blog\/author\/hcartres\/","name":"Orthocell","image":{"@type":"ImageObject","@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/0aab809366bb46167bf34d1c56223f53c568b96a5870f19d01139e3e4a20c2f1?s=96&d=mm&r=g","width":96,"height":96,"caption":"Orthocell"}},{"@type":"WebPage","@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#webpage","url":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/","name":"Video | Proactive Investors Interview \u2013 September 2020 - Orthocell EU\/UK","description":"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.","inLanguage":"en-GB","isPartOf":{"@id":"\/eu-uk\/#website"},"breadcrumb":{"@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#breadcrumblist"},"author":{"@id":"\/eu-uk\/blog\/author\/hcartres\/#author"},"creator":{"@id":"\/eu-uk\/blog\/author\/hcartres\/#author"},"image":{"@type":"ImageObject","url":"\/eu-uk\/wp-content\/uploads\/sites\/6\/2020\/09\/Proactive-Interview-Sept-2020.png","@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#mainImage","width":1052,"height":590},"primaryImageOfPage":{"@id":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/#mainImage"},"datePublished":"2020-09-22T15:46:20+10:00","dateModified":"2021-09-09T16:15:25+10:00"},{"@type":"WebSite","@id":"\/eu-uk\/#website","url":"\/eu-uk\/","name":"Orthocell EU\/UK","inLanguage":"en-GB","publisher":{"@id":"\/eu-uk\/#organization"}}]},"og:locale":"en_GB","og:site_name":"Orthocell EU\/UK -","og:type":"article","og:title":"Video | Proactive Investors Interview \u2013 September 2020 - Orthocell EU\/UK","og:description":"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.","og:url":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/","article:published_time":"2020-09-22T05:46:20+00:00","article:modified_time":"2021-09-09T06:15:25+00:00","twitter:card":"summary_large_image","twitter:title":"Video | Proactive Investors Interview \u2013 September 2020 - Orthocell EU\/UK","twitter:description":"Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process."},"aioseo_meta_data":[],"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/orthocell.com\/eu-uk\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"\/eu-uk\/blog\/category\/video\/\" title=\"Video\">Video<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tVideo | Proactive Investors Interview \u2013 September 2020\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/orthocell.com\/eu-uk"},{"label":"Video","link":"\/eu-uk\/blog\/category\/video\/"},{"label":"Video | Proactive Investors Interview &#8211; September 2020","link":"\/eu-uk\/blog\/2020\/09\/22\/video-proactive-investors-interview-september-2020\/"}],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/2576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=2576"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/2576\/revisions"}],"predecessor-version":[{"id":2577,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/2576\/revisions\/2577"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/2592"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=2576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=2576"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=2576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}